Conserved HBV and HCV sequences useful for gene silencing
AssigneeAlnylam Pharmaceuticals, Inc.
InventorsCatherine J. Pachuk, Chandrasekhar Satishchandran, Vincent R. Zurawski, Liat Mintz
Life of this patent
Estimating the term…
Abstract
Conserved consensus sequences from known hepatitis B virus strains and known hepatitis C virus strains, which are useful in inhibiting the expression of the viruses in mammalian cells, are provided. These sequences are useful to silence the genes of HBV and HCV, thereby providing therapeutic utility against HBV and HCV viral infection in humans.
Claims7
A method for inhibiting expression of a polynucleotide sequence of hepatitis B virus in an in vivo mammalian cell comprising administering to said cell a double-stranded RNA effector molecule selected from the group consisting of:
- 1) a molecule consisting of the sequence of SEQ ID NO:
- 58 hybridized to a molecule with the reverse complement sequence of SEQ ID NO:
- 58;
- 2) a molecule consisting of the sequence of SEQ ID NO:
- 59 hybridized to a molecule with the reverse complement of SEQ ID NO:
- 59;
- and 3) a combination of the molecules of (1) and (2);
- wherein U is substituted for T, and wherein each effector dsRNA optionally comprises a single-stranded nucleotide sequence linking the sequence of SEQ ID NO:
- 58 or SEQ ID NO:
- 59 to its respective reverse-complement sequence.
A composition for inhibiting expression of a polynucleotide sequence of hepatitis B virus in an in vivo mammalian cell comprising a double-stranded RNA effector molecule selected from the group consisting of:
- 1) a molecule consisting of the sequence of SEQ ID NO:
- 58 hybridized to a molecule with the reverse complement sequence of SEQ ID NO:
- 58;
- 2) a molecule consisting of the sequence of SEQ ID NO:
- 59 hybridized to a molecule with the reverse complement of SEQ ID NO:
- 59;
- and 3) a combination of the molecules of (1) and (2);
- wherein U is substituted for T, and wherein each effector dsRNA optionally comprises a single-stranded nucleotide sequence linking the sequence of SEQ ID NO:
- 58 or SEQ ID NO:
- 59 to its respective reverse-complement sequence.
Dependencies are inferred from the claim text.